@entity730 in @entity753 : potential role of the XXXX gene.

@entity1 @entity754 @entity753 @entity730 @entity3667 @entity460 @entity729 @entity21317 @entity165
BACKGROUND: We have previously reported premature, extensive @entity730 in @entity1 with homozygous @entity753 (hmzFH) due to mutations in the @entity754 gene ( @entity754 ). The objective of this study was to measure the degree of @entity730 in heterozygous FH (htzFH) compared to both hmzFH and controls. We hypothesized that the @entity754 gene may contribute to @entity730 in a gene-dosage effect. METHOD: @entity1 with htzFH due to the French Canadian mutation ( @entity21317 kb del. null allele) were selected. All @entity1 underwent computed tomographic scan to measure @entity729 . We used 22 hmzFH @entity1 from our previous study and @entity1 undergoing computed tomographic virtual colonoscopy as controls. RESULTS: Mean age for htzFH was 50 +/- 15 years; initial @entity165 level before treatment was 10.45 +/- 1.73 mmol/ @entity3667 cardiovascular events occurred in 9 of 17 @entity1 . A strong correlation between age and @entity460 score was found (r = 0.72, P = .0016). There was a strong correlation between the @entity165 -year score (an index of lifelong @entity165 burden) and the aortic @entity460 score (r = 0.62, P = .0105). @entity730 in htzFH subjects occurred later than in hmzFH @entity1 , but much earlier than in controls, suggesting a gene-dosage effect of @entity754 mutations and aortic @entity460 deposition. CONCLUSION: @entity730 was observed in @entity1 with htzFH but presented at a later time and were less extensive than in hmzFH (34 vs 14 years, respectively). Because @entity730 may be partly independent of serum @entity165 levels in @entity1 with @entity753 , implications for screening and the timing of treatment initiation may need reassessment.
